Asthma

Atrial Fibrillation

Autoimmune Diseases

Biologics

Biosimilars

Blood Cancer

Breast Cancer

COVID-19

Cardiovascular Diseases

Depression

Dermatology

Diabetes

Digital Health

Drug Coverage

Duchenne Muscular Dystrophy

Eyecare

Friedreich Ataxia

Gene Therapy

Graft Versus Host Disease

Heart Failure

Hemophilia

Hypertrophic Cardiomyopathy (HCM)

Leukemia and Lymphoma

Liver Disease

Lung Cancer

Mental Health

Multiple Sclerosis

NSCLC

Neonatal Care

Nephrology

Obstetrics-Gynecology & Women's Health

Oncology

Opioids

PTSD

Pain

Pediatrics

Plaque Psoriasis

Population Health

Post-Acute Care

Prescription Digital Therapeutics

Pulmonary Arterial Hypertension

Reproductive Health

Respiratory Conditions

Safety & Recalls

Skin Cancer

Sleep Disorders

Solid Tumors

Spinal Muscular Atrophy

Substance Use Disorder

The Improving Patient Access Podcast

Type I Diabetes

Type II Inflammation

Ulcerative Colitis

Urology

Urothelial Carcinoma

Vaccines

Women's Health

News

Media

Between the Lines

Expert Interviews

K-Cast

Medical World News

Podcasts

Population Health Perspectives

Conferences

Partners

Publications

All Publications

MHE Publication

Formulary Watch Supplements

Formulary Watch Spotlights

Supplements And Featured Publications

Events

Virtual Events

CME/CE

Resources

Emerging Leaders

Interactive Tools

PBM Leaders

PBMI Innovators

PBM Directory

Subscribe

Videos

The financial balancing act between providers, government programs and commercial insurers, according to Christoph Dankert, chief network officer of Carrum Health.

The Shifting Landscape of Healthcare Payments

Articles

Patients addicted to opioids receive less mental health care if they are only covered by public insurance, compared with patients receiving care through alternate funding, according to a recent study published in Addiction Science & Clinical Practice.

Medicare and Medicaid Patients With Opioid Addiction Less Likely to Receive Care, Study Shows

Here’s what you missed this week on Managed Healthcare Executive.

MHE Week in Review – 84% of Healthcare Leaders Worried About Business, 92% of Medicare and Medicaid Enrollees Experience Care Delay

Employers are key to transforming healthcare by creating competitive, cost-effective networks independent of federal policy changes, according to Christoph Dankert, chief network officer of Carrum Health. 

Navigating Healthcare's Future: An Insider's View on Network Strategy, Employer Innovation and Policy Challenges

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Managed Healthcare Executive - Payer and Population Health Insights

Facebook

LinkedIn

Resource Centers

Eye Care

Spotlight

Dermatology Conference Coverage

Emerging Leaders in Healthcare

AMCP Annual

K-Cast: Optimizing Narcolepsy Care

Business

Business Strategy

Chronic Disease

Consumers

Drug Costs

Drug Pipeline

Formulary

Health Management

Health/Disease Strategy

Hospitals & Providers

Industry Analysis

Pharmacy

Politics and Policy

Practice Management

Reimbursement

Technology

1rem

Clinical

Karen M. Winkfield, MD, PhD; Narjust Florez, MD, FASCO; Gilberto de Lima Lopes Junior, MD, MBA, FASCO; Coral Olazagasti, MD; Vonetta M. Williams, MD, PhD

 Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

Extreme weather leads to autoimmune disease flare-ups, which can cause a loss of refrigerated medication, according to the results of recent research from the Autoimmune Association. 

Extreme Weather Tied to Autoimmune Disease Flare-ups

The new biosimilar, Tyenne, was approved in both an IV and a subcutaneous forms to treat inflammatory conditions such as arthritis.

FDA Approves Second Biosimilar of Actemra

Celltrion’s application is based on data from a phase 3 trial of patients with rheumatoid arthritis comparing its biosimilar with Actemra.

Celltrion USA Seeks Approval for Actemra Biosimilar

The IV formulation, a monthly 30-minute, weight-based dosing option, has a wholesale acquisition cost of $2,115 per vial. It will be available in the fourth quarter.

FDA Approves IV Formulation of Cosentyx

Biogen is still evaluating launch timeline for Tofidence, and information on pricing will be available closer to launch.

FDA Approves First Biosimilar of Arthritis Med Actemra

Inflammatory bowel disease is a diverse disease that affects people all over the globe. This diversity in setting and treatment options makes it difficult for researchers to estimate the exact cost of care, according to Johan Burisch, M.D., Ph.D., a gastroenterologist at Hvidovre Hospital in Denmark. 

The Challenges of Estimating IBD Care Cost 

Rates of inflammatory bowel diseases (IBD) such as Crohn’s and ulcerative colitis are rising globally, but the range of costs associated with it are poorly understood, according to a research paper entitled The Cost of Inflammatory Bowel Disease Care: How to Make it Sustainable 

Clinical Gastroenterology and Hepatology 

last month by lead author Johan Burisch, M.D., Ph.D., a gastroenterologist at Hvidovre Hospital in Denmark.

In high-income countries, care estimates range anywhere from $9,000 to $12,000 per person annually, according to the research data in the paper.

 Burisch explained that IBD care cost depends largely on where the patient lives and their disease severity.

“For example, the United States has very, very high costs compared to European countries, because the healthcare system is different,” Burisch said.

He also explained that advancements in care have contributed to costs over time.

“If we go back to a couple of decades before we had expensive biological treatments, costs were mainly caused by inpatient care, surgeries and hospitalizations, and this has, over the years, changed,” Burisch said. “Now, it's primarily outpatient care and the medications that are causing the high costs.”

Environmental factors like diet and early antibiotic use have an impact on the gut microbiome and can contribute to inflammatory bowel disease (IBD), explained Ashwin N.  Ananthakrishnan, M.D., M.P.H., MGH, associate professor of medicine at Massachusetts General Hospital.

The Gut Microbiome’s Essential Role in IBD

The gut microbiome is the collection of microorganisms including bacteria, fungi and viruses that live in the human digestive tract. Inflammatory bowel disease (IBD) is a group of chronic conditions that cause inflammation of the digestive tract, caused by a disturbance in the microbiome. The two main types of IBD are ulcerative colitis and Crohn’s disease.

Ashwin N. Ananthakrishnan, M.D., M.P.H., MGH, associate professor of medicine at Massachusetts General Hospital and author of Diet and Microbiome-Directed Therapy 2.0 for IBD, 

, sat down with Managed Healthcare Executive to explain the different environmental factors associated with IBD and how the microbiome can be altered to address IBD progression.

“If you look at IBD and what we've understood so far, we've uncovered over 300 potential genetic variants that are associated with IBD, but if you put them all together, they still explain only about 30% at the most of why people get Crohn's or ulcerative colitis. So still, the vast majority of why people get these conditions remains unexplained, except perhaps in large part, by the environment,” Ananthakrishnan said.“We now recognize the [gut microbiome] is central to the inflammation associated with IBD.”

Environmental factors like diet and early antibiotic use have an impact on the gut microbiome and can contribute to inflammatory bowel disease (IBD), explained Ashwin N. Ananthakrishnan, M.D., M.P.H., MGH, associate professor of medicine at Massachusetts General Hospital.

Exciting Developments With Subcutaneous Biologics

Video content above is prompted by the following questions:

What about subcutaneous biologics excited you the most when they came out? What were your main concerns?

A leading gastroenterologist highlights her initial thoughts about subcutaneous biologics.

Innovations Associated With IV Biologics

What about IV biologics excited you the most when they came out? What were your main concerns?

Dr. Seminerio uncovers what excited her about IV biologics when they first came to market.

Overall Experience With Intravenous Biologics

How long have you been using IV biologics in your practice, for which indications, and what has your overall experience been like?

Dr. Jennifer Seminerio discusses what what her overall perspective with intravenous biologics in gastrointestinal diseases 

An expert in the field of rheumatology predicts how the treatment landscape will evolve for intravenous and subcutaneous therapies.

Future Predictions for Intravenous and Subcutaneous Biologics

How has the introduction of IV biosimilars impacted your treatment decisions? Do you see a role for subcutaneous biosimilars in the future?

Do you foresee IV and subcutaneous route of administration always having a role moving forward? How do you see the treatment landscape changing?




Jill Zouzoulas, M.D., FACR, describes the best practices for incorporating patient perspectives when determining the ideal route of administration for those with rheumatologic diseases.

Incorporating Patient Perspectives When Determining a Route of Administration for Biologic Therapies

How do you evaluate the costs between IV vs. subcutaneous therapies when deciding which route of administration to use in patients?

Patient perspectives have been analyzed in those taking IV biologics for rheumatoid arthritis. What did the results show, and do they factor into your treatment decisions?



Autoimmune Diseases

Latest News